Precision Medicine and Cardiac Channelopathies: Human iPSCs Take the Lead

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Sudden cardiac death (SCD) is a significant cause of mortality globally, particularly in younger populations.
• A substantial percentage of sudden unexpected deaths in individuals under 35 lack autopsied structural cardiac abnormalities, implicating genetic ion channelopathies.
• Recognized genetic channelopathies include long QT syndrome (LQTS), Brugada syndrome (BrS), short QT syndrome (SQTS), and catecholaminergic polymorphic ventricular tachycardia (CPVT).

Purpose of the Study:

• To review critical challenges and recent advancements in the identification, risk stratification, and clinical management of cardiac ion channel disorders.
• To highlight the role of precision medicine (PM) and artificial intelligence (AI) in understanding genetic mechanisms.
• To emphasize the utility of human induced pluripotent stem cell (iPSC) platforms for resolving refractory clinical issues in channelopathies.

Main Methods:

• Literature review of recent advancements in cardiac ion channel disorders.
• Analysis of genetic testing, risk stratification, and clinical management strategies.
• Exploration of precision medicine, artificial intelligence, and iPSC-based platforms.

Main Results:

• Significant progress in understanding ion channelopathy genetics has improved early diagnosis and prevention of SCD.
• Emerging applications of PM and AI offer new avenues for comprehending genetic underpinnings.
• iPSC-based platforms show promise in addressing complex clinical challenges associated with these disorders.

Conclusions:

• Cardiac ion channelopathies are critical, often genetically determined, causes of sudden cardiac death.
• Advancements in genetic understanding, coupled with PM and AI, are enhancing diagnostic and therapeutic approaches.
• iPSC technology provides a powerful tool for elucidating disease mechanisms and developing targeted treatments.